AURA BIOSCIENCES INC (AURA) competitors & alternatives
Health Care · NASDAQ
AURA BIOSCIENCES INC (AURA)'s top competitors and alternatives — its most similar public companies — include CASTLE BIOSCIENCES INC (CSTL), IOVANCE BIOTHERAPEUTICS INC (IOVA), ADC THERAPEUTICS SA (ADCT), SELLAS LIFE SCIENCES GROUP INC (SLS), KURA ONCOLOGY INC (KURA), VERASTEM INC (VSTM), PERSPECTIVE THERAPEUTICS INC (CATX), NURIX THERAPEUTICS INC (NRIX), CYTOMX THERAPEUTICS INC (CTMX), WHITEHAWK THERAPEUTICS INC (WHWK), ORIC PHARMACEUTICALS INC (ORIC) and Revolution Medicines (RVMD). These are AURA BIOSCIENCES INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top AURA competitors & alternatives
-
CASTLE BIOSCIENCES INCCSTLHealth Care
Castle Biosciences provides specialized molecular diagnostic tests to improve risk stratification and personalized treatment decisions for patients with skin…
$24.81 (as of 2026-07-22) · market cap $749M
-
IOVANCE BIOTHERAPEUTICS INCIOVAHealth Care
Iovance delivers Amtagvi, the first FDA-approved individualized TIL cell therapy for advanced melanoma, with a pipeline expanding to lung cancer and sarcoma…
$5.17 (as of 2026-07-22) · market cap $2.3B
-
ADC THERAPEUTICS SAADCTHealth Care
ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma.
$1.24 (as of 2026-07-22) · market cap $158M
-
SELLAS LIFE SCIENCES GROUP INCSLSHealth Care
SELLAS Life Sciences is a clinical-stage biotech developing targeted immunotherapies and small molecule inhibitors to treat a variety of hematologic and solid…
$12.08 (as of 2026-07-22) · market cap $2.2B
-
KURA ONCOLOGY INCKURAHealth Care
Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
$10.54 (as of 2026-07-22) · market cap $944M
-
VERASTEM INCVSTMHealth Care
A biopharmaceutical company developing targeted therapies for RAS/MAPK pathway-driven cancers, with a newly FDA-approved combination treatment for KRAS-mutated…
$5.89 (as of 2026-07-22) · market cap $527M
-
PERSPECTIVE THERAPEUTICS INCCATXHealth Care
Perspective Therapeutics is a clinical-stage oncology company pioneering targeted alpha therapy (TAT) to treat cancer through a proprietary radiopharmaceutical…
$2.97 (as of 2026-07-22) · market cap $337M
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
CYTOMX THERAPEUTICS INCCTMXHealth Care
CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity,…
$3.33 (as of 2026-07-22) · market cap $724M
-
WHITEHAWK THERAPEUTICS INCWHWKHealth Care
Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload…
$3.99 (as of 2026-07-22) · market cap $216M
-
ORIC PHARMACEUTICALS INCORICHealth Care
ORIC Pharmaceuticals is a clinical-stage oncology company developing targeted therapies for hard-to-treat cancers through precision medicine approaches.
$10.75 (as of 2026-07-22) · market cap $1.1B
-
Revolution MedicinesRVMDHealth Care
A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital.
$183.03 (as of 2026-07-22) · market cap $39.0B
Not quite? Describe exactly what you want →
Peers are AURA BIOSCIENCES INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: AURA BIOSCIENCES INC (AURA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.